Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25424099 | 0.95 | TSHR (0.41) | EPHX2TSHRNPC1RAB9AHPGD | |
| SCHEMBL25424091 | 0.95 | TSHR (0.41) | EPHX2TSHRNPC1RAB9AHPGD | |
| SCHEMBL29039246 | 0.91 | TSHR (0.40) | EPHX2TSHRKMT2AGLASMN1; SMN2 | |
| SCHEMBL19947263 | 0.86 | POLB (0.40) | EPHX2TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL19947264 | 0.86 | POLB (0.40) | EPHX2TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL13731844 | 0.86 | FKBP1A (0.40) | NPC1RAB9AHPGDKMT2AMEN1 | |
| SCHEMBL702497 | 0.82 | ATM (0.43) | HPGDFKBP1ASMN1; SMN2 | |
| SCHEMBL13673248 | 0.82 | CYP1A2 (0.47) | EPHX2TSHRGLASMN1; SMN2 | |
| SCHEMBL1779547 | 0.81 | L3MBTL1 (0.38) | NPC1RAB9AHPGDKMT2AFKBP1A | |
| SCHEMBL3035722 | 0.81 | L3MBTL1 (0.38) | NPC1RAB9AHPGDKMT2AFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264400-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | EPHX2 1631/4885TSHR 1575/4885NPC1 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.